PRKG1 and oral cavity squamous cell carcinoma: PGK was found to be downregulated in cisplatin-resistant cell lines of oral squamous cell carcinoma, and a study of kidney renal clear cell carcinoma found that PGK enhanced sorafenib resistance and tumorigenesis by regulating glycolysis, which is a promising drug target (Nakatani et al., 2005; He et al., 2024).